PRO CAR-301

About PromiCell

PromiCell is a clinical-stage biotech company developing next-generation CAR-T and TCR therapies for cancer, with a focus on addressing the limitations of current treatments. Its core technological innovations include IL-18 cytokine armoring to overcome tumor resistance and a hypoxic manufacturing process to enhance cell durability. The company's pipeline, sourced from Fred Hutchinson Cancer Center and Memorial Sloan Kettering, targets high-need areas like metastatic prostate cancer, leukemia, and sarcoma, with two ongoing clinical trials and several more planned for 2026.

Therapeutic Areas

Other Relapsed/Refractory Acute Myeloid Leukemia (AML) Drugs